Arrowhead製藥 ARWR 深 滬
等待開盤 10-24 09:30:00 美东时间
37.35
-0.280
-0.74%
華盛通- 最 高38.23
- 今 開37.63
- 成交量 125.78万股
- 最 低 36.73
- 昨 收 37.63
- 總市值 51.54亿
- 52周最高 40.289
- 市盈率 靜 --
- 換手率 0.91%
- 52周最低 9.57
- 委 比 42.63%
- 總股本 1.38亿
- 歷史最高 93.66
- 量 比 0.65
- 振 幅 3.99%
- 歷史最低 1.22
- 每 手 1
- 風險率 6.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
Arrowhead Pharmaceuticals Files To Begin Phase 1/2a Trial for Dual-Target RNAi Drug ARO-DIMER-PA, Aims To Treat Atherosclerotic Cardiovascular Disease From Mixed Hyperlipidemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's investigational RNA interference
10-07 19:34
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
09-29 19:11
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
Roche deal to buy 89bio boosts MASH space
Shares of companies focused on developing drugs for a liver condition called metabolic dysfunction-associated steatohepatitis (MASH) traded higher on Thursday after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) a...
09-18 22:41
Arrowhead Pharmaceuticals Sues Ionis Over Patent Dispute
Arrowhead Pharmaceuticals ( ($ARWR) ) has provided an announcement. On Septembe...
09-11 20:00
Arrowhead Pharma Files Request For Regulatory Clearance To Initiate Phase 1/2a Clinical Trial Of ARO-MAPT, Investigational RNAi Therapeutic For Tauopathies
- In preclinical studies presented today at the RNA Leaders USA Congress 2025, investigational ARO-MAPT demonstrated potent and long-lasting MAPT mRNA and Tau protein suppression with uniform distribution
09-10 19:31
美股周涨跌榜 | 医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%
医药牛股频出！细胞动力周涨幅达50%，新药迎关键进展；美国联合医疗周涨超31%，肺纤维化治疗取得重大突破；Lululemon周跌17%，此前下调年度利润及销售额预期>>
09-06 10:02
美股大行评级 | 潜在涨幅91.64%！曼恩凯德生物医疗获HC Wainwright升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持曼恩凯德生物医疗"买入"评级，目标价从9美元升至11美元；杰富瑞：维持Ionis Pharmaceuticals"买入"评级，目标价从83美元升至96美元
09-03 10:20
Arrowhead Pharmaceuticals Inks Global Licensing And Collaboration Agreement With Novartis For ARO-SNCA For Synucleinopathies, Such As Parkinson's Disease; Arrowhead Will Receive $200M As An Upfront Payment And Is Eligible To Receive Up To $2B In Milestone Payments Plus Commercial Sales Royalties
Upon closing, Arrowhead will receive an upfront payment of $200 millionNovartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead's preclinical stage siRNA therapy for the treatment of synucleinopathies,
09-02 19:32
